Supplementary Figures from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

Unknown
December 15, 2023
Cited by 0Open Access
Full Text

Abstract

<p>Supplementary Figure S1-5</p>


Related Papers

No related papers found

Powered by citation graph analysis